Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Atherosclerosis: full-pipeline trial registry
16 of 70 indexed Atherosclerosis trials are currently recruiting.
Corpus placement: #198 of 28,707 conditions by registered trial count.
70 US clinical trials · 16 currently recruiting · #198 of 28,707 conditions by registered trial count
Atherosclerosis: 70 US clinical trials tracked, 16 recruiting.
Atherosclerosis is the subject of 70 registered US clinical trials on ClinicalTrials.gov, 16 of them currently open to new participants. 13 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is National Heart, Lung, and Blood Institute (NHLBI), running 12 of these trials.
Enrollment posture brief
Registry condition atherosclerosis
OPEN 16 | RECR 23% | LATE 13 | EARLY 15 | RANK #198 | SPON 12
Volume-matched condition peers
Nearest open-share peer: Gout (23% recruiting · 35 trials)
Atherosclerosis lists 16 open slots (23% of 70 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Atherosclerosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Atherosclerosis is recruiting below its size-band peers.
16 of 70 indexed trials (22.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Atherosclerosis research.
National Heart, Lung, and Blood Institute (NHLBI) accounts for 12 of 70 trials (17.1%). 44 distinct sponsors appear on at least one study for this condition label.
-
Typical Atherosclerosis enrolment sits around 216 participants.
Median target enrolment is 216 among the 70 trials that report a genuine target (sentinel values excluded). 18 of those (25.7%) plan for fewer than 100 participants.
-
Atherosclerosis splits between interventional and observational designs.
43 interventional and 27 observational studies make up this index (61.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
70 total, page 2 of 2
Carotid Atherosclerotic Plaque Study
University of Wisconsin, Madison
NCT00214006
Pilot Study of Ultrasonic Determined Carotid Plaque Composition
D. Geoffrey Vince
NCT01879397
High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly
Johns Hopkins University
NCT00127218
Using Differences in Peripheral Blood Leukocyte Gene Expression to Determine Cardiovascular Disease Risk
National Heart, Lung, and Blood Institute (NHLBI)
NCT00613158
Racial Differences in Control of Blood Vessel Tone and Blood Flow
National Heart, Lung, and Blood Institute (NHLBI)
NCT00001747
Magnetic Resonance Angiography (MRA) for the Diagnosis of Atherosclerosis
National Institutes of Health Clinical Center (CC)
NCT00001841
Distributed Registry
Stanford University
NCT03898570
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
MedImmune
NCT03654313
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
GlaxoSmithKline
NCT00695305
A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation
Indiana University
NCT02685098
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
National Heart, Lung, and Blood Institute (NHLBI)
NCT00001890
Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome
Florida Atlantic University
NCT00272311
11C-PIB PET Study in MESA at Columbia University
José A. Luchsinger
NCT03981380
Inflammation and Vascular Function in Atherosclerosis
Brigham and Women's Hospital
NCT00760019
PET/CT Imaging Companion Study To ACTG A5314
Massachusetts General Hospital
NCT02312219
Pharmacogenomics of Antiplatelet Response
Johns Hopkins University
NCT02234427
Local Paclitaxel Delivery for SFA Disease
University of Oklahoma
NCT00821028
Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation
National Heart, Lung, and Blood Institute (NHLBI)
NCT00005928
Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects
GlaxoSmithKline
NCT01154114
Indocyanine Green Fluorescence Uptake in Human Carotid Artery Plaque
Massachusetts General Hospital
NCT01873716
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 11 |
| Phase 3 | 5 |
| Phase 4 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Atherosclerosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Atherosclerosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Atherosclerosis page
70 registered trials, 16 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 16 Atherosclerosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Heart, Lung, and Blood Institute (NHLBI) sponsors the most Atherosclerosis trials on record, review their full trial history before evaluating a specific study. See National Heart, Lung, and Blood Institute (NHLBI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Atherosclerosis condition card totals 70 registered trials; most-linked intervention Placebo; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.